Clinical trials: Zika
Zika Virus
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
- Trial name
- NCT04064905
- Testing
- mRNA-1893
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy, Zika
GLS-5700 in Dengue Virus Seropositive Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02887482
- Testing
- GLS-5700
- Where
- 3 sites in Puerto Rico
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Zika, Zika Virus Infection
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside…
- Trial name
- NCT06334393
- Testing
- VLA1601, CpG 1018®, 3M-052-AF
- Where
- 4 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Anemia
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC…
- Trial name
- RedeS (NCT03037164)
- Testing
- INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
- Where
- 16 sites in United States, Puerto Rico and 1 more
- Volunteers
- 692 people
- Sponsor
- Cerus Corporation